FDA issues EUA for Regeneron's COVID-19 mAb cocktail The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on November 21 for the casirivimab and imdevimab monoclonal antibody (mAb) cocktail. The mAb cocktail is for the treatment of mild to moderate symptoms in patients with COVID-19 who are at a high risk for progressing to severe COVID-19.
Immunomic, Colmmune partner on cancer immunotherapy Immunomic Therapeutics and CoImmune Therapeutics have entered into a license agreement for Immunomic to use CoImmune's proprietary dendritic cell process for certain Immunomic cell therapy vaccine programs.
Megadalton joins Waters' Immerse Cambridge labs Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Obsidian, MD Anderson partner on solid tumor cell therapy Obsidian Therapeutics and the University of Texas MD Anderson Cancer Center have entered a multiyear strategic collaboration for the research and development of novel engineered tumor infiltrating lymphocytes for the treatment of solid tumors.
Vivet, Pfizer to begin Wilson's disease gene therapy trial The U.S. Food and Drug Administration (FDA) has cleared Vivet Therapeutics' investigational new drug application for the Gateway study, a phase I/II study evaluating Vivet's VTX-801, a proprietary, investigational gene therapy for the treatment of Wilson's disease.